东方生物
(688298)
| 流通市值：37.82亿 | | | 总市值：37.82亿 |
| 流通股本：2.02亿 | | | 总股本：2.02亿 |
| 利润表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 营业总收入 | 717,529,186.54 | 464,165,739.75 | 256,264,814.4 | 947,379,903.5 |
| 营业总成本 | 993,939,164.06 | 666,531,461.19 | 346,307,060.81 | 1,341,786,186.68 |
| 其他经营收益 | | | | |
| 营业利润 | -277,566,159.29 | -202,331,507.46 | -92,816,308.75 | -582,244,786.91 |
| 利润总额 | -279,723,697.88 | -203,329,846.72 | -92,825,886.77 | -583,493,837.49 |
| 净利润 | -310,871,778.42 | -232,060,997.06 | -98,701,196.07 | -597,405,207.55 |
| 每股收益 | | | | |
| 其他综合收益 | -21,879,142.42 | -16,066,354.42 | -4,955,418.9 | -28,782,723.77 |
| 综合收益总额 | -332,750,920.84 | -248,127,351.48 | -103,656,614.97 | -626,187,931.32 |
| 资产负债表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 流动资产: | | | | |
| 流动资产合计 | 2,929,705,396.58 | 3,016,626,162.25 | 3,038,342,839.47 | 3,256,255,673.06 |
| 非流动资产: | | | | |
| 非流动资产合计 | 3,872,581,119.06 | 3,876,055,680.33 | 3,854,708,064.37 | 3,882,690,154.26 |
| 资产总计 | 6,802,286,515.64 | 6,892,681,842.58 | 6,893,050,903.84 | 7,138,945,827.32 |
| 流动负债: | | | | |
| 流动负债合计 | 857,243,817.76 | 891,968,025.41 | 802,319,402.47 | 831,862,638.17 |
| 非流动负债: | | | | |
| 非流动负债合计 | 181,552,994.61 | 160,002,346.99 | 105,855,774.65 | 221,407,998.19 |
| 负债合计 | 1,038,796,812.37 | 1,051,970,372.4 | 908,175,177.12 | 1,053,270,636.36 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 5,679,602,782.49 | 5,754,773,515.13 | 5,894,007,566.15 | 5,992,716,114.22 |
| 股东权益合计 | 5,763,489,703.27 | 5,840,711,470.18 | 5,984,875,726.72 | 6,085,675,190.96 |
| 负债和股东权益合计 | 6,802,286,515.64 | 6,892,681,842.58 | 6,893,050,903.84 | 7,138,945,827.32 |
| 现金流量表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 877,141,378.58 | 609,645,032.03 | 333,154,649.16 | 1,078,293,500.07 |
| 经营活动现金流出小计 | 962,620,907.41 | 652,811,157.08 | 362,263,405.36 | 1,272,192,548.63 |
| 经营活动产生的现金流量净额 | -85,479,528.83 | -43,166,125.05 | -29,108,756.2 | -193,899,048.56 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 399,901,553.25 | 397,663,965.78 | 282,827,046.33 | 2,103,084,273.85 |
| 投资活动现金流出小计 | 827,170,508.81 | 1,417,476,605.56 | 1,001,200,992.05 | 1,525,483,256.95 |
| 投资活动产生的现金流量净额 | -427,268,955.56 | -1,019,812,639.78 | -718,373,945.72 | 577,601,016.9 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 312,697,838.71 | 252,136,910.05 | 92,795,303.99 | 384,000,000 |
| 筹资活动现金流出小计 | 168,609,027.38 | 105,632,033.21 | 64,858,294.17 | 617,881,458.69 |
| 筹资活动产生的现金流量净额 | 144,088,811.33 | 146,504,876.84 | 27,937,009.82 | -233,881,458.69 |
| 汇率变动对现金及现金等价物的影响 | -59,558,709.86 | -45,147,841.6 | -24,957,288.44 | -24,409,916.74 |
| 现金及现金等价物净增加额 | -428,218,382.92 | -961,621,729.59 | -744,502,980.54 | 125,410,592.91 |
| 期末现金及现金等价物余额 | 1,207,467,508.87 | 674,064,162.2 | 891,182,911.25 | 1,635,685,891.79 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | -961,621,729.59 | - | 125,410,592.91 |